CNBCLean R·
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Read at CNBC →
Business · 1 sources covering this
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/4a658c3e1da2870fc7dda83404e8bf0ba4b40950" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="We're raising our price target on Eli Lilly as the obesity-drug boom rolls on"></iframe>
